Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Growth factor and cytokine profiling in systemic sclerosis and control plasma samples

From: Multiplex cytokine analysis of dermal interstitial blister fluid defines local disease mechanisms in systemic sclerosis

Biologic function   Healthy control samples SSc samples P value
Innate immunity IFNα2 20.16 (14.47 to 29.72) 28.86 (18.41 to 39.83) 0.33
  IL-1α 2.51 (2.51 to 5.78) 2.51 (2.51 to 17.91) 0.37
  IL-1B 1.65 (1.65 to 1.65) 1.65 (1.65 to 1.72) 0.40
  IL-1RA 34.52 (25.15 to 44.60) 57.36 (35.85 to 83.9) 0.03
  IL-6 2.66 (2.66 to 2.66) 2.66 (2.66 to 2.69) 0.29
  IL-12p40 4.77 (4.77 to 5.63) 12.92 (4.77 to 28.25) 0.07
  IL-12p70 3.78 (2.97 to 5.64) 4.73 (3.46 to 7.78) 0.34
  IL-15 2.45 (2.45 to 2.45) 2.45 (2.45 to 2.76) 0.29
  IP-10 297 (189.75 to 448) 396 (317.5 to 544.5) 0.27
  TNFα 4.38 (3.98 to 6) 6.98 (4.98 to 8.84) 0.04
Adaptive immunity IFNγ 3.7 (2.99 to 4.49) 4.89 (3.26 to 6.82) 0.38
  IL-2 1.47 (1.47 to 1.47) 1.47 (1.47 to 2.14) 0.29
  IL-3 0.36 (0.34 to 0.54) 0.57 (0.34 to 0.82) 0.54
  IL-4 2.83 (2.83 to 2.83) 2.83 (2.83 to 3.65) 0.20
  IL-5 1.93 (1.93 to 1.93) 1.93 (1.93 to 1.93) 0.52
  IL-7 2.28 (1.78 to 2.89) 2.66 (2.14 to 3.85) 0.47
  IL-9 1.24 (1.24 to 1.24) 1.24 (1.24 to 1.24) 0.40
  IL-10 1.55 (1.03 to 2.91) 2.86 (1.48 to 5.18) 0.13
  IL-13 1.65 (1.65 to 1.65) 1.65 (1.65 to 1.65) 0.40
  IL-17α 2.33 (1.75 to 2.38) 2.49 (1.61 to 3.38) 0.38
  sCD40L 9,800.01 (9,800.01 to 9,800.01) 9,800.01 (9,800.01 to 9,800.01) 0.87
  TNFβ 2.34 (2.34 to 2.76) 2.34 (2.34 to 3.26) 0.49
Chemokines Eotaxin 95.3 (67.43 to 129.75) 97.64 (76.3 to 132.5) 0.87
  Fractalkine 50.87 (41.87 to 57.36) 62.72 (49.39 to 72.85) 0.21
  GRO 627.5 (477.25 to 655) 556 (383.5 to 709) 0.52
  IL-8 3.11 (1.97 to 4.32) 3.29 (2.78 to 4.07) 0.58
  MCP-1 236.5 (217.5 to 240.5) 230 (157.5 to 274) 0.83
  MCP-3 8.84 (5.73 to 13.41) 14.68 (8.63 to 19.76) 0.06
  MDC 718 (686.75 to 785.5) 696 (624 to 835) 0.71
  MIP-1α 1.6 (1.6 to 2.03) 1.77 (1.6 to 3.99) 0.24
  MIP-1β 18.47 (16.15 to 24.73) 21.92 (17.75 to 27.85) 0.52
  RANTES 1,869 (1,723.5 to 2,090.5) 1,473 (1,234 to 1,626) 0.01
Growth factors EGF 49.36 (38.36 to 144.75) 63.8 (47.29 to 128) 0.83
  Flt-3 L 5.07 (5.07 to 5.07) 5.07 (5.07 to 5.59) 0.29
  GCSF 35.64 (33.17 to 39.41) 43.21 (34.88 to 54.04) 0.21
  GMCSF 7.9 (6.04 to 10.71) 12.84 (9.15 to 20.06) 0.05
  PDGF-AA 1,518.5 (889 to 1,852) 1,300 (825.5 to 1,601.5) 0.49
  PDFG-BB 4,137 (2,686.5 to 5,063.75) 4,573 (3,646 to 5,609.5) 0.43
  TGFα 0.41 (0.41 to 0.41) 0.41 (0.41 to 0.41) 0.40
  FGF-2 59.52 (48.78 to 80.7) 78.75 (57.53 to 95.77) 0.12
  VEGF 71.78 (50.92 to 91.04) 130 (81.12 to 202) 0.08
  1. Data presented as median concentration (pg/ml) (25th to 75th percentile). Permutation analysis: significance analysis of microarrays for Excel, Wilcoxon rank-sum test. Significant results are in bold, taken as P <0.05. EGF, epidermal growth factor; FGF, fibroblast growth factor; Flt, FMS-like tyrosine kinase; GCSF, granulocyte colony-stimulating factor; GMCSF, granulocyte–macrophage colony-stimulating factor; GRO, growth regulated oncogene; IFN, interferon; IL, interleukin; IL-1RA, interleukin-1 receptor antagonist; IP-10, Interferon gamma induced protein 10; MCP, monocyte chemotactic protein; MIP, macrophage inflammatory protein; PDGF, platelet-derived growth factor; RANTES, regulated on activation normal T cell expressed and secreted; SSc, systemic sclerosis; TGF-α, transforming growth factor alpha; TNF-α, tumour necrosis factor alpha; VEGF, vascular endothelial cell growth factor.